Elesclomol clinical trials on-going in acute myeloid leukemia and ovarian cancer-
"Synta Pharmaceuticals Corp. SNTA +0.67% -- A report published in the peer-reviewed journal PLoS ONE demonstrate how a novel yeast screening platform pioneered by researchers at the University of Toronto was used to elucidate the mechanism of action of elesclomol, a first-in-class drug that targets cancer cell metabolism and is currently being clinically developed by Synta Pharmaceuticals Corp. of Lexington, Massachusetts. Elesclomol is currently in clinical trials in both solid tumor and hematologic cancers, including a study in combination with paclitaxel in ovarian cancer and a single agent study in acute myeloid leukemia (AML) currently being conducted at Princess Margaret Hospital in Toronto....."
Blogger's Note: PLOS is an open access publisher; PLOS link - 3 publications:
Blogger's Note: PLOS is an open access publisher; PLOS link - 3 publications:
- itochondrial Electron Transport Is the Cellular Target of the Oncology Drug Elesclomol Drug Elesclomol Elesclomol Targets Mitochondrial ETC ... Mitochondrial Electron Transport Is the Cellular Target of the Oncology Drug Elesclomol ... Elesclomol is a first-in-class investigational drug PLoS ONE: Research Article, published 11 Jan 2012 10.1371/journal.pone.0029798
- Role of Mitochondrial Electron Transport Chain Complexes in Capsaicin Mediated Oxidative Stress Leading to Apoptosis in Pancreatic Cancer Cells agents such as Elesclomol or Trisenx are currently PLoS ONE: Research Article, published 25 May 2011 10.1371/journal.pone.0020151 Views: 1093Citations: Yes
- Cancer Biomarker Discovery: The Entropic Hallmark . Elesclomol) works by inducing apoptosis via a mechanism PLoS ONE: Research Article, published 18 Aug 2010 10.1371/journal.pone.0012262
